Literature DB >> 30705851

Specific copy number changes as potential predictive markers for adjuvant chemotherapy in non-small cell lung cancer.

Mitsuo Sato1.   

Abstract

Entities:  

Year:  2018        PMID: 30705851      PMCID: PMC6328691          DOI: 10.21037/tlcr.2018.11.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  25 in total

Review 1.  The Aurora-A/TPX2 complex: a novel oncogenic holoenzyme?

Authors:  Italia Anna Asteriti; Wilhelmina Maria Rensen; Catherine Lindon; Patrizia Lavia; Giulia Guarguaglini
Journal:  Biochim Biophys Acta       Date:  2010-08-12

2.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

3.  Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II.

Authors:  M Jin; S Inoue; T Umemura; J Moriya; M Arakawa; K Nagashima; H Kato
Journal:  Lung Cancer       Date:  2001-11       Impact factor: 5.705

4.  High-resolution genomic profiles of human lung cancer.

Authors:  Giovanni Tonon; Kwok-Kin Wong; Gautam Maulik; Cameron Brennan; Bin Feng; Yunyu Zhang; Deepak B Khatry; Alexei Protopopov; Mingjian James You; Andrew J Aguirre; Eric S Martin; Zhaohui Yang; Hongbin Ji; Lynda Chin; Ronald A Depinho
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-27       Impact factor: 11.205

5.  Characterizing the cancer genome in lung adenocarcinoma.

Authors:  Barbara A Weir; Michele S Woo; Gad Getz; Sven Perner; Li Ding; Rameen Beroukhim; William M Lin; Michael A Province; Aldi Kraja; Laura A Johnson; Kinjal Shah; Mitsuo Sato; Roman K Thomas; Justine A Barletta; Ingrid B Borecki; Stephen Broderick; Andrew C Chang; Derek Y Chiang; Lucian R Chirieac; Jeonghee Cho; Yoshitaka Fujii; Adi F Gazdar; Thomas Giordano; Heidi Greulich; Megan Hanna; Bruce E Johnson; Mark G Kris; Alex Lash; Ling Lin; Neal Lindeman; Elaine R Mardis; John D McPherson; John D Minna; Margaret B Morgan; Mark Nadel; Mark B Orringer; John R Osborne; Brad Ozenberger; Alex H Ramos; James Robinson; Jack A Roth; Valerie Rusch; Hidefumi Sasaki; Frances Shepherd; Carrie Sougnez; Margaret R Spitz; Ming-Sound Tsao; David Twomey; Roel G W Verhaak; George M Weinstock; David A Wheeler; Wendy Winckler; Akihiko Yoshizawa; Soyoung Yu; Maureen F Zakowski; Qunyuan Zhang; David G Beer; Ignacio I Wistuba; Mark A Watson; Levi A Garraway; Marc Ladanyi; William D Travis; William Pao; Mark A Rubin; Stacey B Gabriel; Richard A Gibbs; Harold E Varmus; Richard K Wilson; Eric S Lander; Matthew Meyerson
Journal:  Nature       Date:  2007-11-04       Impact factor: 49.962

6.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.

Authors:  Jude Kendall; Qing Liu; Amy Bakleh; Alex Krasnitz; Ken C Q Nguyen; B Lakshmi; William L Gerald; Scott Powers; David Mu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-09       Impact factor: 11.205

7.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.

Authors:  Mitsuo Sato; Melville B Vaughan; Luc Girard; Michael Peyton; Woochang Lee; David S Shames; Ruben D Ramirez; Noriaki Sunaga; Adi F Gazdar; Jerry W Shay; John D Minna
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

8.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

Authors:  Montserrat Sanchez-Cespedes; Paola Parrella; Manel Esteller; Shuji Nomoto; Barry Trink; James M Engles; William H Westra; James G Herman; David Sidransky
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

9.  Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

Authors:  George Simon; Anupama Sharma; Xueli Li; Todd Hazelton; Frank Walsh; Charles Williams; Alberto Chiappori; Eric Haura; Tawee Tanvetyanon; Scott Antonia; Alan Cantor; Gerold Bepler
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

10.  SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.

Authors:  Adam J Bass; Hideo Watanabe; Craig H Mermel; Soyoung Yu; Sven Perner; Roel G Verhaak; So Young Kim; Leslie Wardwell; Pablo Tamayo; Irit Gat-Viks; Alex H Ramos; Michele S Woo; Barbara A Weir; Gad Getz; Rameen Beroukhim; Michael O'Kelly; Amit Dutt; Orit Rozenblatt-Rosen; Piotr Dziunycz; Justin Komisarof; Lucian R Chirieac; Christopher J Lafargue; Veit Scheble; Theresia Wilbertz; Changqing Ma; Shilpa Rao; Hiroshi Nakagawa; Douglas B Stairs; Lin Lin; Thomas J Giordano; Patrick Wagner; John D Minna; Adi F Gazdar; Chang Qi Zhu; Marcia S Brose; Ivan Cecconello; Ulysses Ribeiro; Suely K Marie; Olav Dahl; Ramesh A Shivdasani; Ming-Sound Tsao; Mark A Rubin; Kwok K Wong; Aviv Regev; William C Hahn; David G Beer; Anil K Rustgi; Matthew Meyerson
Journal:  Nat Genet       Date:  2009-10-04       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.